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ABSTRACT 44 
Objectives: Until the introduction of fidaxomicin, antimicrobial treatment for Clostridium 45 
difficile infection (CDI) was limited to metronidazole and vancomycin. The changing 46 
epidemiology of CDI and emergence of epidemic C. difficile PCR ribotype 027 necessitates 47 
continued surveillance to identify shifts in antibiotic susceptibility. ClosER, currently the 48 
largest pan-European epidemiological study of C. difficile ribotype distribution and antibiotic 49 
susceptibility, aimed to undertake antimicrobial resistance surveillance pre- and post-50 
introduction of fidaxomicin.  51 
Methods: Between July 2011 and July 2014, 39 sites across 22 European countries 52 
submitted 2830 C. difficile isolates for ribotyping, toxin testing and susceptibility testing to 53 
metronidazole, vancomycin, fidaxomicin, rifampicin, moxifloxacin, clindamycin, imipenem, 54 
chloramphenicol and tigecycline. 55 
Results: Ribotypes 027, 014, 001, 078, 020, 002, 126, 015 and 005 were most frequently 56 
isolated, while emergent ribotypes 198 and 356 were identified in Hungary and Italy, 57 
respectively. All isolates were susceptible to fidaxomicin, with scarce resistance to 58 
metronidazole (0.2% [n=6/2694]), vancomycin (0.1% [n=2/2694]) and tigecycline (0%). 59 
Rifampicin, moxifloxacin and clindamycin resistance was evident in multiple ribotypes. Lack 60 
of ribotype diversity correlated with greater antimicrobial resistance. Epidemic ribotypes 61 
(027/001) were associated with multiple antimicrobial resistance, and ribotypes 017, 018 and 62 
356 with high-level resistance. Additional factors may also influence local ribotype 63 
prevalence.  64 
Conclusions: Fidaxomicin susceptibility was retained post-introduction, and resistance to 65 
metronidazole and vancomycin was rare. Continued surveillance is needed, with more 66 
accurate classification and clarification of ribotype subtypes to further understand their role in 67 
the spread of resistance. Other factors may also influence changes in prevalence of C. 68 
difficile ribotypes with reduced antibiotic susceptibility. 69 
  70 
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Introduction 71 
Clostridium difficile infection (CDI) is a major cause of nosocomial diarrhoea and a problem 72 
in healthcare environments and the community, causing significant morbidity and mortality 73 
worldwide [1]. So-called ‘hypervirulent’ strains, such as those belonging to polymerase chain 74 
reaction (PCR) ribotype (RT) 027 [2,3], are increasingly represented among clinical isolates, 75 
and the incidence and severity of CDI is rising [4]. A recent report on antimicrobial resistance 76 
cites C. difficile as a microorganism with an urgent threat level [5]. 77 
Vancomycin and metronidazole are commonly used treatments for CDI. Fidaxomicin, a 78 
macrocyclic antimicrobial with potent anti-C. difficile activity, was introduced to the European 79 
market in 2011 for the treatment of CDI. European marketing authorisation for fidaxomicin 80 
included a commitment to undertake antimicrobial resistance surveillance pre- and post-81 
introduction. The three-year ClosER (Clostridium difficile European Resistance) in vitro 82 
surveillance study aimed to: identify and monitor longitudinal susceptibility of 83 
contemporaneous C. difficile clinical isolates to antibiotics used for CDI treatment and those 84 
implicated in selection pressure; establish a comprehensive susceptibility database baseline 85 
for ongoing surveillance; and provide data on geographical distribution of clinical C. difficile 86 
strain types with analysis by region across Europe [6]. 87 
Presented here are final epidemiological and antimicrobial susceptibility data for C. difficile 88 
isolates collected over the three-year study period: pre-fidaxomicin introduction (July 2011–89 
June 2012), and post-fidaxomicin introduction (July 2012–July 2014). Preliminary first-year 90 
data (pre-fidaxomicin introduction) are described elsewhere [6], but are updated here to 91 
include further results from sites/submissions for that period which were previously 92 
unavailable.  93 
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Methods 95 
Study design 96 
The study design of ClosER has been described in full elsewhere [6]. Briefly, 41 sites from 97 
28 European countries participated and were asked to submit 25 C. difficile isolates or toxin-98 
positive faecal samples from de-duplicated CDI cases each year. No further stipulations 99 
were made regarding selection of isolates/samples. Centres were mainly national or regional 100 
C. difficile referral laboratories selected using the European Study Group on C. difficile 101 
(ESGCD) network, and with ESGCD approval. 102 
Isolates or faecal samples were submitted to a central laboratory (in Leeds, UK) for C. 103 
difficile culture, PCR ribotyping, determination of toxin status by cell culture cytotoxicity 104 
assay, and susceptibility to metronidazole, vancomycin, rifampicin, fidaxomicin, imipenem, 105 
moxifloxacin, clindamycin, chloramphenicol and tigecycline. 106 
 107 
Culture and toxin testing 108 
Alcohol-shocked faecal specimens/C. difficile isolates were inoculated on to cycloserine-109 
cefoxitin-egg-yolk agar (Lab M, Heywood, Lancashire, UK) with lysozyme and cultured 110 
anaerobically for 48 hours at 37°C. Forty-eight-hou r anaerobic brain–heart infusion broth 111 
culture supernatants of each test isolate were added to a Vero cell culture cytotoxicity assay 112 
with Clostridium sordellii antitoxin (Pro-Lab Diagnostics, Bromborough, UK) neutralisation. 113 
 114 
Ribotyping 115 
PCR ribotyping, using capillary electrophoresis, was performed on each isolate by the C. 116 
difficile Ribotyping Network Reference Laboratory at Leeds Teaching Hospitals Trust, Leeds, 117 
UK [7]. Ribotypes were assigned against the UK C. difficile reference library at Leeds. 118 
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 119 
Antimicrobial susceptibility testing 120 
Susceptibility of isolates (minimum inhibitory concentrations [MICs]) to metronidazole, 121 
vancomycin, rifampicin, chloramphenicol (Sigma), moxifloxacin (Bayer), clindamycin, 122 
tigecycline (Pfizer), imipenem (MSD) and fidaxomicin (Astellas) were determined using a 123 
Clinical and Laboratory Standards Institute agar incorporation method with Wilkins–Chalgren 124 
agar [6,8,9] and breakpoints, as previously described [6]. 125 
 126 
Cumulative resistance scores 127 
MIC results for each isolate were designated susceptible (S), intermediately resistant (I) or 128 
fully resistant (R), according to breakpoints, and assigned a score (S=0, I=1 and R=2). A 129 
cumulative resistance score (CRS) based on susceptibility to each of the nine antimicrobials 130 
tested was then generated for each isolate. Thus, an isolate that was fully susceptible to 131 
four, intermediately resistant to two, and resistant to three antimicrobials would generate a 132 
CRS of 8 (0 + 0 + 0 + 0 + 1 + 1 + 2 + 2 + 2). Isolates were grouped by country, and mean 133 
CRSs were generated for each country over the three years.  134 
 135 
Results 136 
Over three years, 2830 samples/isolates (from 39 sites in 22 countries) were submitted to 137 
the central laboratory for testing, yielding 2694 C. difficile isolates (95.3%). Of these, 95.6% 138 
(n=2577) were toxin-positive. 139 
 140 
PCR ribotyping  141 
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In Year 1, 114 known PCR RTs were isolated from samples; in Year 2, 144; and in Year 3, 142 
120. The most commonly isolated European RT was RT027, which accounted for: 12.2% 143 
(n=115/943) in Year 1; 11.8% (n=112/948) in Year 2; and 12.6% (n=101/804) in Year 3. The 144 
prevalence of other RTs is presented in Table 1. 145 
RT prevalence differed by region, with certain countries exhibiting highly predominant RTs, 146 
and others showing a diverse range of RTs (Fig. 1a–c). RT027 was particularly associated 147 
with Denmark, Hungary, Italy and Poland; RTs 018 and 078 with Italy; RTs 176 and 017 with 148 
the Czech Republic; and a high prevalence of RT001 with Latvia and Slovakia. 149 
Emergent RTs 198 and 356 were also evident, and exclusive to Hungary and Italy, 150 
respectively (Fig. 1a–c). 151 
RT diversity scores were calculated for each country (total number of RTs detected in that 152 
country divided by the number of isolates tested from that country). Scores closest to 1 and 153 
0 indicated the greatest and least diversity of RTs, respectively. Belgium submitted the 154 
greatest diversity of RTs in Years 1 and 2, with scores of 0.96 and 0.80, respectively.  155 
 156 
Antimicrobial susceptibility  157 
All isolates were susceptible to fidaxomicin, with geometric mean MICs of 0.04–0.05 mg/L 158 
(Table 2a), and a normal unimodal distribution for all study years (Fig. 2). Among prevalent 159 
RTs, only RT027 and RT198 showed evidence of increased geometric mean MICs: in Years 160 
1–3, from 0.04 to 0.08 mg/L for RT027; and from 0.04 to 0.10 mg/L for RT198 (Table 3). 161 
Metronidazole, vancomycin and tigecycline were active against 97.9% (n=2692/2698), 162 
98.6% (n=2659/2698) and 100.0%, respectively, of isolates tested. There was little variation 163 
in sensitive, intermediate and resistant isolates collected across Europe during Years 1–3 164 
(Table 2b). Reduced metronidazole susceptibility was mainly observed for RT027 and 165 
RT198, and is reflected in higher geometric mean metronidazole MICs (Table 3). 166 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
8 
 
Higher geometric mean vancomycin MICs were observed for RT018 (2.00 mg/L) and RT356 167 
(2.28 mg/L, Year 1 only) (Table 3). No particular RTs were associated with vancomycin 168 
resistance.  169 
The proportion of isolates showing rifampicin resistance was similar in Years 1 and 2, with a 170 
slight reduction in Year 3 (Table 2b). Rifampicin resistance was notable in Hungary (38.7–171 
56.6% [n =29/75–43/76]), Italy (36.6–47.0% [n=34/93–39/83]) and the Czech Republic 172 
(40.0–64.0% [n=10/25–14/22]). Rifampicin resistance in Denmark decreased from 40.9% 173 
(n=9/22) in Year 1, to 18.2% (n=4/22) by Year 3, due to a decrease in the number of RT027 174 
isolates. In Poland, rifampicin resistance was low in Year 1 (5.0% [n=1/20]), but rates 175 
increased in Years 2 and 3 (37.9% [n=11/29] and 44.0% [n=11/25], respectively). Rifampicin 176 
resistance was evident in multiple RTs, notably in RT027, RT001, RT018, RT356, RT017, 177 
RT176 and RT198 (Table 3). 178 
Moxifloxacin and clindamycin resistance was widespread, particularly among some of the 179 
more prevalent RTs (Table 3). Moxifloxacin resistance decreased over Years 1–3 from 180 
39.5% (n=372/943) to 33.5% (n=269/803). Clindamycin resistance increased from 49.8% 181 
(n=470/943) to 64.3% (n=516/803) (Table 2b), but showed variations in the proportion of 182 
resistant isolates from the same country, possibly due to fluctuations in individual RT 183 
prevalence. 184 
The majority of isolates were sensitive to imipenem (Table 2b). Geometric mean MICs were 185 
marginally higher for RT027 and RT198 than for most other RTs during the study period 186 
(Table 3). During Years 2 and 3, there was evidence of decreasing imipenem susceptibility 187 
to RT017 (geometric mean MIC: 9.8 mg/L and 10.6 mg/L, respectively) (Table 3). Most 188 
isolates were susceptible to chloramphenicol (Table 2b). For RT017, geometric mean MICs 189 
increased from 7.66 mg/L (Year 1) to 14.59 mg/L (Year 3) (Table 3). Reduced susceptibility 190 
to tigecycline (>0.25 mg/L) was scarce; geometric mean MICs were marginally raised for 191 
RT012 in Years 1 and 2 (Table 3). 192 
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 193 
Multiple antimicrobial resistance  194 
During the study, antimicrobial resistance to three or more antibiotics was evident for RTs 195 
001, 106, 018, 356 and 012. RTs 027, 017 and 198 showed resistance to five or more 196 
antibiotics, including metronidazole, rifampicin, moxifloxacin, clindamycin, imipenem and 197 
chloramphenicol (Table 3). 198 
 199 
Antimicrobial susceptibility by country (Fig. S1a,b,c) 200 
Poland, Latvia, the Czech Republic and Hungary had consistently high CRSs in all three 201 
years. Cyprus also showed a high CRS in Year 1, associated with a high prevalence of 202 
RT027; however, scores decreased consistently in subsequent years despite the continued 203 
high prevalence of RT027. This was due to decreasing resistance of RT027 isolates over the 204 
three years. Sweden consistently had the lowest CRSs in all years (0.88, 0.52 and 1.16).  205 
There was a significant inverse correlation between the number of RTs identified in a locality 206 
and the mean CRS (Pearson correlation Year 1, r=−0.55, p=0.0095; Year 2, r=−0.59, 207 
p=0.003; Year 3, r=0.47, p=0.03). This indicated lower antimicrobial resistance levels in 208 
countries with a greater diversity of C. difficile RTs. 209 
 210 
Discussion 211 
This is the largest pan-European study of C. difficile RT and antibiotic susceptibility 212 
epidemiology to date. Surveillance of over 2800 isolates from 22 European countries 213 
showed a diverse array of 144 RTs. The most commonly isolated RTs were broadly similar 214 
to those already reported [4,10]. Previously described epidemic or highly prevalent RTs 215 
(014/20, 027, 001/072 and 078) [6,10,11] were similar, but inter-country variations were 216 
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apparent in the relative prevalence of particular strains. This is consistent with the endemic 217 
and epidemic spread of C. difficile previously documented [10–12].  218 
Compared with the most recent surveillance results from EUCLID (a European, multicentre, 219 
prospective, biannual, point-prevalence study of CDI in hospitalised patients with diarrhoea), 220 
in which the incidence of RT027 was 19% among 1196 C. difficile isolates tested [4], our 221 
study found a lower incidence (11.8–12.6%) for this RT. This variability may result from the 222 
greater number of isolates tested in our study, leading to different levels of prevalence for 223 
each RT. Our study also demonstrated that RTs reported previously as highly prevalent 224 
(RT001 in Latvia and Slovakia, RT027 in Poland and Hungary, and RT017 and RT176 in the 225 
Czech Republic) remained so in those countries. 226 
The emergence of RT356 in Italy in Year 1, with its accompanying high levels of 227 
antimicrobial resistance, has been described [6,13] (24th European Congress of Clinical 228 
Microbiology and Infectious Diseases [ECCMID], abstract R483). PCR banding profiles of 229 
RT018 and RT356 are closely related (94% similarity) and genome sequencing of these 230 
isolates may inform both strain provenance and resistance development [6]. As reported 231 
previously [6], methodological advances have allowed greater RT discrimination, which 232 
improves understanding of local fluctuations and highlights the need for a consensus on RT 233 
nomenclature. 234 
Consistent with previously reported good activity (range 0.007–1.000 mg/L) [14], fidaxomicin 235 
was the most widely active CDI treatment in this study, with no clear evidence of reduced 236 
susceptibility or resistance. There was scant evidence of decreased susceptibility to 237 
fidaxomicin from Year 1 (pre-fidaxomicin introduction) through Years 2 and 3 (post-238 
fidaxomicin introduction). Similarly, a recent US National Sentinel Surveillance Study 239 
reported no change in fidaxomicin activity against C. difficile (n=925 isolates) over 12 240 
months following fidaxomicin introduction [15]. 241 
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It has been suggested that so-called ‘hypervirulent’ C. difficile strains (including RT027) may 242 
be less susceptible to fidaxomicin than other RTs [14]. Only small differences in fidaxomicin 243 
susceptibility were observed between RTs in our study. Notably, the increase in geometric 244 
mean fidaxomicin MICs for RT027 was merely 0.04 mg/L over three years. The significance 245 
of this observation is questionable, particularly in the context of high faecal fidaxomicin 246 
concentrations during therapy (>1000 g/g), which are >5000-fold higher than the MIC90 247 
[16]. 248 
Reduced metronidazole susceptibility was uncommon across all years, and most evident 249 
among RT027 and RT198, as previously described [17] (25th European Congress of Clinical 250 
Microbiology and Infectious Diseases [ECCMID], abstract EV0260). RT198 and RT027 are 251 
closely related [18]; it is therefore possible that a mechanistic similarity between the two RT 252 
subtype influences reduced metronidazole susceptibility. Continued surveillance is 253 
necessary to increase knowledge about emerging RTs with genomic similarities to highly 254 
virulent and dynamic strains. 255 
Vancomycin resistance was scarce and not consistently RT-associated. Again, the clinical 256 
significance of higher vancomycin MICs is unclear in the light of high gut vancomycin 257 
concentrations in vivo [19]. 258 
Our study confirms previously reported associations between prevalent RTs (e.g. RT027 and 259 
RT001) and resistance to moxifloxacin, clindamycin and chloramphenicol [12,20], with some 260 
evidence of location clustering (chloramphenicol-resistant RT001 in Germany, The 261 
Netherlands and Latvia). To date, imipenem resistance has not been well-documented in C. 262 
difficile, but intermediate and complete resistance was evident throughout our study, 263 
particularly in RTs 027,198 and 017.  264 
This study underlines the association of well-known epidemic RTs 027 and 001 with multiple 265 
antimicrobial resistance, and highlights the association and emergence of other RTs (017, 266 
018, 198, 356) with high levels of resistance, as previously described [6]. Increasing multiple 267 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
12 
 
antimicrobial resistance was observed in RT198 in Hungary, RT027 in Italy, and RT017 in 268 
the Czech Republic, indicating a potential role for local antimicrobial prescribing as a 269 
selection pressure.  270 
RT027 remained prevalent in Cyprus and became progressively less resistant to some 271 
antimicrobials, but retained high levels of fluoroquinolone resistance. Recent evidence 272 
suggests that resistance to macrolide–lincosamide–streptogramin antibiotics may confer a 273 
fitness cost to C. difficile, while others, e.g. fluoroquinolone resistance, do not [21,22]. 274 
Fluoroquinolone resistance may therefore be maintained even in the absence of 275 
fluoroquinolone pressure. European Centre for Disease Prevention and Control data show 276 
that both fluoroquinolone and macrolide–lincosamide–streptogramin antibiotic consumption 277 
in Cyprus decreased to their lowest levels in eight years [23]. This may indicate that 278 
antimicrobial pressure is only part of the picture and other factors influence the emergence 279 
and decline in prevalence of C. difficile RTs. 280 
There was a consistent, significant inverse correlation between the number of RTs identified 281 
in a locality and the mean CRSs, indicating lower antimicrobial resistance levels among 282 
countries with a greater diversity of C. difficile RTs. This may be because of the introduction 283 
of mandatory reporting programmes, with consequent increased awareness, antimicrobial 284 
stewardship and infection control interventions decreasing the rates of endemic RTs. 285 
Interestingly, the UK had a low mean CRS and a low RT diversity score, possibly due to the 286 
large denominator sample size (n=123–150 isolates), which also included the greatest 287 
number of RTs from a single country.  288 
Selection bias may also be possible, as we requested only 25 patient de-duplicated, toxin-289 
positive faecal samples (or C. difficile isolates) collected during each study period, but made 290 
no further stipulations. Participating centres were predominantly national or regional C. 291 
difficile reference facilities and therefore some submissions likely included outbreak strains, 292 
possibly influencing the data. In addition, there is inherent sensitivity loss in gathering 293 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
13 
 
international epidemiological surveillance data. However, the similarity of the predominant 294 
RTs between this study and that of Bauer et al. [10], plus the continued presence of 295 
antimicrobial resistance phenotypes among certain prevalent RTs, indicate a degree of 296 
confidence [3]. 297 
In conclusion, our study highlights the epidemiological and antimicrobial findings for C. 298 
difficile isolates collected pre- and post-fidaxomicin introduction across Europe. It highlights 299 
the high level of retained susceptibility to fidaxomicin across Europe two years post-300 
introduction, and the rarity of resistance to metronidazole and vancomycin. It also reinforces 301 
the potential impact of ‘hypervirulent’ strains of C. difficile, such as RT027 and RT001, and 302 
emerging RTs (198, 356) on geographical resistance patterns, supporting the hypothesis 303 
that increased awareness, infection control and antimicrobial stewardship may result in 304 
increased RT diversity and reduced antimicrobial resistance. Ultimately, this study highlights 305 
the need for continued surveillance to further understand how the epidemiological landscape 306 
may be affected by the introduction of novel antimicrobial agents against CDI.  307 
  308 
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Tables 438 
 439 
Table 1 440 
Percentage prevalence (≥1%) of Clostridium difficile PCR ribotypes in the 3 years from July 441 
2011 to July 2014 of the ClosER study  442 
 443 
Year 1 (n=943) Year 2 (n=948) Year 3 (n=804) 
Ribotype n 
% 
prevalence Ribotype n 
% 
prevalence Ribotype n 
% 
prevalence 
027 115 12.2 027 112 11.8 027 101 12.6 
001 86 9.1 014 89 9.4 014 85 10.6 
078 76 8.1 001 77 8.1 001 63 7.8 
014 74 7.8 002 53 5.6 020 44 5.5 
020 38 4.0 078 53 5.6 078 43 5.4 
126 35 3.7 020 49 5.2 126 41 5.1 
002 34 3.6 005 31 3.3 002 35 4.4 
015 32 3.4 015 31 3.3 005 31 3.9 
005 31 3.3 126 31 3.3 015 22 2.7 
106 24 2.5 018 28 3.0 046 19 2.4 
023 23 2.4 023 20 2.1 106 18 2.2 
018 21 2.2 017 18 1.9 017 15 1.9 
356 21 2.2 046 17 1.8 176 13 1.6 
012 19 2.0 012 14 1.5 018 12 1.5 
011 16 1.7 198 14 1.5 003 11 1.4 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
21 
 
017 16 1.7 106 13 1.4 010 11 1.4 
046 15 1.6 056 11 1.2 081 11 1.4 
087 15 1.6 029 10 1.1 011 10 1.2 
056 11 1.2 039 10 1.1 023 10 1.2 
081 10 1.1 070 10 1.2 
      012 9 1.1 
      198 8 1.0 
PCR, polymerase chain reaction. 444 
Bold type indicates the nine most commonly isolated ribotypes across Years 1–3. 445 
 446 
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Table 2a 448 
MIC50, MIC90 and geometric mean MICs of Clostridium difficile isolates in the three years of 449 
the ClosER study (July 2011–July 2014)  450 
mg/L Years M V FDX RIF MXF CLINDA IMI CHLOR TIG 
MIC50 Y1 0.25 1 0.06 0.002 2 4 4 8 0.06 
MIC50 Y2 0.25 0.5 0.06 0.002 2 8 4 4 0.03 
MIC50 Y3 0.25 0.5 0.06 0.002 2 8 4 4 0.03 
MIC50 All years 0.25 0.5 0.06 0.002 2 8 4 4 0.03 
MIC90 Y1 2 2 0.125 32 32 128 8 8 0.06 
MIC90 Y2 1 1 0.125 32 32 128 8 8 0.06 
MIC90 Y3 1 1 0.125 32 32 128 8 8 0.06 
MIC90 All years 1 1 0.125 32 32 128 8 8 0.06 
Geometric 
mean MIC Y1 0.37 0.76 0.04 0.01 4.79 5.72 4.75 5.82 0.05 
Geometric 
mean MIC Y2 0.33 0.70 0.05 0.01 3.90 7.61 3.88 5.39 0.04 
Geometric 
mean MIC Y3 0.29 0.70 0.05 0.01 3.73 9.18 4.17 6.06 0.04 
Geometric 
mean MIC 
All 
years 0.56 1.22 0.05 0.01 4.14 7.26 4.26 5.73 0.04 
CHLOR, chloramphenicol; CLINDA, clindamycin; FDX, fidaxomicin; IMI, imipenem; M, 451 
metronidazole; MIC, minimum inhibitory concentrations; MXF, moxifloxacin; RIF, rifampicin; 452 
TIG, tigecycline; V, vancomycin.    453 
MIC50/MIC90, minimum inhibitory concentration at which 50%/90% of isolates are inhibited. 454 
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Table 2b 456 
Proportions of sensitive, intermediately sensitive and resistant Clostridium difficile isolates in 457 
the three years of the ClosER study (July 2011–July 2014) 458 
 
Years M V FDX RIF MXF CLINDA IMI CHLOR TIG 
Sensitive (%) Y1 97.9 96.7 100.0 80.5 58.7 37.6 62.7 92.9 100.0 
Y2 98.1 98.8 100.0 82.1 64.5 29.1 77.3 93.1 100.0 
Y3 96.9 99.8 100.0 86.8 66.0 18.3 78.1 91.5 100.0 
All 
years 
97.9 98.6 100.0 83.2 63.1 29.0 72.6 92.8 100.0 
Intermediately 
sensitive (%) 
Y1 2.0 2.4  6.0 1.8 12.4 30.1 3.5  
Y2 1.3 0.6  3.7 1.0 13.7 19.7 2.6  
Y3 2.6 0.1  1.5 0.5 17.4 19.7 5.1  
All 
years 
1.9 1.1  3.9 1.1 14.4 23.3 3.7  
Resistant (%) Y1 0.1 0.9  13.5 39.5 49.8 7.2 3.6  
Y2 0.1   13.7 34.1 56.7 2.3 3.7  
Y3 0.5 0.1  11.6 33.5 64.3 2.2 3.4  
All 
years 
0.2 0.1  13.0 35.8 56.6 4.0 3.6  
CHLOR, chloramphenicol; CLINDA, clindamycin; FDX, fidaxomicin; IMI, imipenem; M, 459 
metronidazole; MXF, moxifloxacin; RIF, rifampicin; TIG, tigecycline; V, vancomycin. 460 
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Table 3 462 
Geometric mean MICs of prevalent Clostridium difficile PCR ribotypes in the three years of 463 
the ClosER study (July 2011–July 2014) 464 
  Ribotype M V FDX RIF MXF CLINDA IMI CHLOR TIG 
Y1 027 1.41 0.70 0.04 0.472 22.16 3.55 7.13 4.91 0.04 
Y2 027 1.47 0.81 0.07 0.303 22.71 4.82 6.94 5.15 0.04 
Y3 027 1.24 0.71 0.08 0.351 18.35 6.34 6.69 5.72 0.03 
Y1 001 0.47 0.83 0.01 0.007 12.18 48.63 5.18 8.74 0.04 
Y2 001 0.33 0.64 0.01 0.006 14.06 41.84 3.48 6.84 0.04 
Y3 001 0.38 0.66 0.02 0.006 13.45 54.40 5.08 7.91 0.03 
Y1 078 0.27 0.63 0.04 0.003 3.39 2.85 3.18 5.07 0.05 
Y2 078 0.21 0.69 0.05 0.003 2.63 4.93 3.04 4.21 0.04 
Y3 078 0.19 0.62 0.05 0.003 2.51 6.92 3.09 4.93 0.04 
Y1 014 0.27 0.65 0.06 0.002 2.41 5.15 4.31 5.87 0.05 
Y2 014 0.25 0.60 0.06 0.003 1.95 4.83 3.16 4.90 0.04 
Y3 014 0.22 0.63 0.06 0.003 2.00 8.20 3.77 5.97 0.04 
Y1 020 0.31 0.73 0.07 0.002 2.63 6.43 4.80 5.66 0.05 
Y2 020 0.27 0.64 0.06 0.002 2.07 4.06 2.96 5.09 0.05 
Y3 020 0.22 0.65 0.06 0.002 1.68 6.94 3.42 5.75 0.04 
Y1 126 0.23 0.66 0.04 0.003 9.37 15.69 3.62 5.38 0.06 
Y2 126 0.23 0.60 0.05 0.003 5.79 25.40 3.10 4.59 0.05 
Y3 126 0.17 0.62 0.04 0.003 4.58 15.47 3.05 5.52 0.04 
Y1 002 0.24 0.65 0.05 0.002 2.13 6.80 4.00 5.89 0.04 
Y2 002 0.25 0.74 0.06 0.003 1.86 5.40 3.04 4.74 0.03 
Y3 002 0.19 0.74 0.07 0.002 2.25 7.54 3.55 5.17 0.03 
Y1 015 0.20 0.62 0.04 0.001 1.58 3.15 5.30 5.30 0.05 
Y2 015 0.23 0.70 0.04 0.003 1.54 1.65 3.23 4.00 0.04 
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Y3 015 0.19 0.60 0.04 0.002 1.21 3.31 4.13 5.15 0.03 
Y1 005 0.26 0.82 0.05 0.003 2.50 4.28 5.12 5.00 0.05 
Y2 005 0.23 0.83 0.05 0.002 1.62 4.70 3.10 4.19 0.05 
Y3 005 0.22 0.87 0.06 0.003 1.60 5.59 3.42 5.47 0.04 
Y1 106 0.65 0.82 0.07 0.002 8.48 6.17 6.54 6.92 0.04 
Y2 106 0.40 0.90 0.04 0.004 5.22 14.38 4.95 7.58 0.05 
Y3 106 0.37 0.71 0.08 0.003 5.44 8.00 4.67 4.67 0.04 
Y1 023 0.19 0.72 0.06 0.003 1.83 0.83 3.65 6.48 0.05 
Y2 023 0.25 0.75 0.07 0.002 1.39 1.34 3.59 4.46 0.04 
Y3 023 0.22 0.76 0.07 0.002 1.74 1.00 3.25 5.66 0.04 
Y1 018 0.41 2.00 0.04 2.072 35.33 4.42 5.56 5.04 0.04 
Y2 018 0.31 0.69 0.05 1.111 11.89 7.43 5.80 4.76 0.04 
Y3 018 0.20 0.67 0.03 1.425 11.31 8.00 5.34 5.04 0.04 
Y1 356 0.61 2.28 0.04 18.871 50.80 8.55 5.86 4.88 0.04 
Y2 356 0.57 0.57 0.05 32.000 32.00 13.93 6.06 4.59 0.05 
Y3 356 0.13 1.00 0.03 32.000 16.00 32.00 4.00 4.00 0.03 
Y1 012 0.27 0.72 0.05 0.005 2.40 51.42 5.36 9.60 0.08 
Y2 012 0.39 0.91 0.05 0.002 1.81 55.17 3.81 6.56 0.08 
Y3 012 0.29 0.79 0.06 0.002 2.52 69.12 4.00 11.76 0.06 
Y1 017 0.27 0.65 0.02 0.925 18.22 43.34 5.91 7.66 0.04 
Y2 017 0.22 0.61 0.02 1.187 13.59 39.24 9.81 14.75 0.05 
Y3 017 0.22 0.72 0.05 0.420 9.19 50.80 10.56 14.59 0.05 
Y1 198 1.19 0.39 0.04 0.006 5.66 0.77 7.34 4.00 0.03 
Y2 198 1.64 0.55 0.08 0.015 23.78 12.49 7.61 4.88 0.03 
Y3 198 1.68 0.50 0.10 0.004 24.68 4.00 8.00 8.00 0.04 
Y1 All isolates 0.37 0.76 0.04 0.008 4.79 5.72 4.75 5.82 0.05 
Y2 All isolates 0.33 0.70 0.05 0.009 3.90 7.61 3.88 5.39 0.04 
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Y3 All isolates 0.29 0.70 0.05 0.007 3.73 9.18 4.17 6.06 0.04 
CHLOR, chloramphenicol; CLINDA, clindamycin; FDX, fidaxomicin; IMI, imipenem; M, 465 
metronidazole; MICs, minimum inhibitory concentrations; MXF, moxifloxacin; PCR, 466 
polymerase chain reaction; RIF, rifampicin; TIG, tigecycline; V, vancomycin. 467 
Bold type indicates higher geometric mean MICs of prevalent Clostridium difficile PCR 468 
ribotypes.  469 
  470 
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Figure legends 471 
 472 
Fig. 1. Percentage prevalence of Clostridium difficile PCR ribotypes in 22 European 473 
countries. (a) Year 1 of the ClosER study. There were no submissions from Finland in Year 474 
1. (b) Year 2 of the ClosER study. (c) Year 3 of the ClosER study. There were no 475 
submissions from Finland or Slovakia in Year 3.  476 
ªC. difficile ribotypes with prevalence <1% per given year. PCR, polymerase chain reaction. 477 
 478 
Fig. 2. Fidaxomicin MIC distribution for all isolates in Years 1, 2 and 3 of the ClosER study.  479 
MIC, minimum inhibitory concentration. 480 
 481 
Supplementary Fig. S1. Distribution of cumulative antimicrobial resistance of Clostridium 482 
difficile in 22 European countries: mean cumulative resistance scores. (a) Year 1 of the 483 
ClosER study. (b) Year 2 of the ClosER study. (c) Year 3 of the ClosER study.  484 
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